Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | STS | P08842 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182303 | 0.96 | ALDH1A1 (0.63) | KMT2ATSHRMEN1HPGDALDH1A1 | |
| SCHEMBL8210703 | 0.90 | KMT2A (0.55) | KMT2AMEN1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL9058559 | 0.88 | KMT2A (0.58) | KMT2ATSHRMEN1HPGDALDH1A1 | |
| SCHEMBL14497203 | 0.86 | ALDH1A1 (0.58) | KMT2ATSHRMEN1HPGDALDH1A1 | |
| SCHEMBL20274773 | 0.85 | TP53 (0.50) | KMT2ATSHRMEN1TP53THRB | |
| SCHEMBL2862442 | 0.85 | ALDH1A1 (0.60) | KMT2ATSHRMEN1ALDH1A1TP53 | |
| SCHEMBL18608789 | 0.84 | MEN1 (0.58) | KMT2AMEN1TP53SMN1; SMN2MAPT | |
| SCHEMBL17523583 | 0.83 | HRH3 (0.48) | KMT2ATSHRMEN1HPGDALDH1A1 | |
| SCHEMBL6981012 | 0.82 | SMN1; SMN2 (0.65) | KMT2AMEN1HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL1939593 | 0.82 | SMN1; SMN2 (0.65) | KMT2AMEN1HPGDALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592347-B2 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| EP-1615909-B1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GRIN2A, GRIK5, GRIN2C | KMT2A 371/4885TSHR 2805/4885MEN1 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.